Brain metastasis screening in the molecular age

Author:

Tabor Joanna K12ORCID,Onoichenco Amanda12,Narayan Vinayak2,Wernicke A Gabriella3,D’Amico Randy S2,Vojnic Morana4

Affiliation:

1. SUNY Downstate College of Medicine, Brooklyn , NY , USA

2. Department of Neurological Surgery, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell , New York, NY , USA

3. Department of Radiation Medicine, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell , New York, NY , USA

4. Northwell Health Cancer Institute at Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell , New York, NY , USA

Abstract

Abstract The incidence of brain metastases (BM) amongst cancer patients has been increasing due to improvements in therapeutic options and an increase in overall survival. Molecular characterization of tumors has provided insights into the biology and oncogenic drivers of BM and molecular subtype-based screening. Though there are currently some screening and surveillance guidelines for BM, they remain limited. In this comprehensive review, we review and present epidemiological data on BM, their molecular characterization, and current screening guidelines. The molecular subtypes with the highest BM incidence are epithelial growth factor receptor-mutated non-small cell lung cancer (NSCLC), BRCA1, triple-negative (TN), and HER2+ breast cancers, and BRAF-mutated melanoma. Furthermore, BMs are more likely to present asymptomatically at diagnosis in oncogene-addicted NSCLC and BRAF-mutated melanoma. European screening standards recommend more frequent screening for oncogene-addicted NSCLC patients, and clinical trials are investigating screening for BM in hormone receptor+, HER2+, and TN breast cancers. However, more work is needed to determine optimal screening guidelines for other primary cancer molecular subtypes. With the advent of personalized medicine, molecular characterization of tumors has revolutionized the landscape of cancer treatment and prognostication. Incorporating molecular characterization into BM screening guidelines may allow physicians to better identify patients at high risk for BM development and improve patient outcomes.

Publisher

Oxford University Press (OUP)

Subject

Surgery,Oncology,Neurology (clinical)

Reference110 articles.

1. Brain metastases admissions in Sweden between 1987 and 2006;Smedby;Br J Cancer.,2009

2. Epidemiology of brain metastases;Nayak;Curr Oncol Rep.,2012

3. Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: A population-based study;Habbous;Neurooncol Adv,2021

4. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system;Barnholtz-Sloan;J Clin Oncol.,2004

5. Mapping distribution of brain metastases: Does the primary tumor matter;Schroeder;J Neurooncol.,2020

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3